195 related articles for article (PubMed ID: 36177046)
1. HLAII peptide presentation of infliximab increases when complexed with TNF.
Casasola-LaMacchia A; Seward RJ; Tourdot S; Willetts M; Kruppa G; Agostino MJ; Bergeron G; Ahyi-Amendah N; Ciarla A; Lu Z; Kim HY; Hickling TP; Neubert H
Front Immunol; 2022; 13():932252. PubMed ID: 36177046
[TBL] [Abstract][Full Text] [Related]
2. Development of a semi-automated MHC-associated peptide proteomics (MAPPs) method using streptavidin bead-based immunoaffinity capture and nano LC-MS/MS to support immunogenicity risk assessment in drug development.
Lee MV; Saad OM; Wong S; LaMar J; Kamen L; Ordonia B; Melendez R; Hassanzadeh A; Chung S; Kaur S
Front Immunol; 2023; 14():1295285. PubMed ID: 38022649
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.
Karle A; Spindeldreher S; Kolbinger F
MAbs; 2016; 8(3):536-50. PubMed ID: 26817498
[TBL] [Abstract][Full Text] [Related]
4. Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies.
Bar-Yoseph H; Pressman S; Blatt A; Gerassy Vainberg S; Maimon N; Starosvetsky E; Ungar B; Ben-Horin S; Shen-Orr SS; Chowers Y;
Gastroenterology; 2019 Nov; 157(5):1338-1351.e8. PubMed ID: 31401142
[TBL] [Abstract][Full Text] [Related]
5. Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody.
Xue L; Hickling T; Song R; Nowak J; Rup B
Clin Exp Immunol; 2016 Jan; 183(1):102-13. PubMed ID: 26400440
[TBL] [Abstract][Full Text] [Related]
6. Limited promiscuity of HLA-DRB1 presented peptides derived of blood coagulation factor VIII.
van Haren SD; Wroblewska A; Herczenik E; Kaijen PH; Ruminska A; ten Brinke A; Meijer AB; Voorberg J
PLoS One; 2013; 8(11):e80239. PubMed ID: 24244658
[TBL] [Abstract][Full Text] [Related]
7. Analytical ultracentrifugation with fluorescence detection system reveals differences in complex formation between recombinant human TNF and different biological TNF antagonists in various environments.
Krayukhina E; Noda M; Ishii K; Maruno T; Wakabayashi H; Tada M; Suzuki T; Ishii-Watabe A; Kato M; Uchiyama S
MAbs; 2017; 9(4):664-679. PubMed ID: 28387583
[TBL] [Abstract][Full Text] [Related]
8. Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti-TNF-α Antibodies after a Single Injection in Mice.
Arnoult C; Brachet G; Cadena Castaneda D; Azzopardi N; Passot C; Desvignes C; Paintaud G; Heuzé-Vourc'h N; Watier H; Gouilleux-Gruart V
J Immunol; 2017 Jul; 199(2):418-424. PubMed ID: 28584008
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells.
Cohen S; Myneni S; Batt A; Guerrero J; Brumm J; Chung S
MAbs; 2021; 13(1):1898831. PubMed ID: 33729092
[TBL] [Abstract][Full Text] [Related]
10. An Engineered Monovalent Anti-TNF-α Antibody with pH-Sensitive Binding Abrogates Immunogenicity in Mice following a Single Intravenous Dose.
Watkins JM; Watkins JD
J Immunol; 2022 Aug; 209(4):829-839. PubMed ID: 35896334
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of TNF-Inhibitors.
Atiqi S; Hooijberg F; Loeff FC; Rispens T; Wolbink GJ
Front Immunol; 2020; 11():312. PubMed ID: 32174918
[TBL] [Abstract][Full Text] [Related]
12. MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity.
Sekiguchi N; Kubo C; Takahashi A; Muraoka K; Takeiri A; Ito S; Yano M; Mimoto F; Maeda A; Iwayanagi Y; Wakabayashi T; Takata S; Murao N; Chiba S; Ishigai M
MAbs; 2018; 10(8):1168-1181. PubMed ID: 30199322
[TBL] [Abstract][Full Text] [Related]
13. Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference.
Marino F; Semilietof A; Michaux J; Pak HS; Coukos G; Müller M; Bassani-Sternberg M
Front Immunol; 2020; 11():1981. PubMed ID: 32983136
[TBL] [Abstract][Full Text] [Related]
14. Identification of Immunodominant HIV-1 Epitopes Presented by HLA-C*12:02, a Protective Allele, Using an Immunopeptidomics Approach.
Chikata T; Paes W; Akahoshi T; Partridge T; Murakoshi H; Gatanaga H; Ternette N; Oka S; Borrow P; Takiguchi M
J Virol; 2019 Sep; 93(17):. PubMed ID: 31217245
[TBL] [Abstract][Full Text] [Related]
15. Differential Serum-intestinal Dynamics of Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.
Bar-Yoseph H; Blatt A; Gerassy S; Pressman S; Mousa A; Sabo E; Waterman M; Ungar B; Ben-Horin S; Chowers Y
J Crohns Colitis; 2022 Jul; 16(6):884-892. PubMed ID: 34849649
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists.
Hamdi H; Mariette X; Godot V; Weldingh K; Hamid AM; Prejean MV; Baron G; Lemann M; Puechal X; Breban M; Berenbaum F; Delchier JC; Flipo RM; Dautzenberg B; Salmon D; Humbert M; Emilie D;
Arthritis Res Ther; 2006; 8(4):R114. PubMed ID: 16859506
[TBL] [Abstract][Full Text] [Related]
17. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
[TBL] [Abstract][Full Text] [Related]
18. Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors.
Hamze M; Meunier S; Karle A; Gdoura A; Goudet A; Szely N; Pallardy M; Carbonnel F; Spindeldreher S; Mariette X; Miceli-Richard C; Maillère B
Front Immunol; 2017; 8():500. PubMed ID: 28529511
[TBL] [Abstract][Full Text] [Related]
19. Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients.
Colman RJ; Portocarrero-Castillo A; Chona D; Hellmann J; Minar P; Rosen MJ
Inflamm Bowel Dis; 2021 Mar; 27(4):507-515. PubMed ID: 32426829
[TBL] [Abstract][Full Text] [Related]
20. Analyzing the effect of peptide-HLA-binding ability on the immunogenicity of potential CD8+ and CD4+ T cell epitopes in a large dataset.
Wang S; Li J; Chen X; Wang L; Liu W; Wu Y
Immunol Res; 2016 Aug; 64(4):908-18. PubMed ID: 27094547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
